| 06.08 14:01 | dpa-AFX: IDEXX Laboratories Q2 24 Earnings Conference Call At 9:00 AM ET |
| 06.08 13:26 | dpa-AFX: *IDEXX LABORATORIES Q2 NET INCOME ATTRIBUTABLE TO STOCKHOLDERS $202.29 MLN VS $224.24 MLN LAST YEAR |
| 06.08 13:25 | dpa-AFX: *IDEXX LABORATORIES Q2 REVENUES UP 6% TO $1.004 BLN; UP 7% ORGANICALLY |
| 06.08 13:24 | dpa-AFX: *IDEXX LABORATORIES UPDATES 2024 REVENUE GUIDANCE TO $3.885 BLN - $3.945 BLN |
| 06.08 12:56 | dpa-AFX: ROUNDUP: IDEXX Laboratories Slashes FY24 Outlook |
| 06.08 12:46 | dpa-AFX: *IDEXX LABORATORIES ADJUSTS 2024 EPS OUTLOOK TO $10.31 - $10.59 |
| 06.08 12:44 | dpa-AFX: IDEXX Laboratories Inc Reports Retreat In Q2 Bottom Line, Misses Estimates |
| 06.08 12:34 | dpa-AFX: *IDEXX LABORATORIES Q2 EPS $2.44; COMPARABLE EPS $3.02 |
| 06.08 12:34 | dpa-AFX: *IDEXX LABORATORIES Q2 EPS $2.44; COMPARABLE EPS $3.02 |
| 04.06 13:03 | dpa-AFX: *IDEXX LABORATORIES ANNOUNCES LAUNCH OF THE CATALYST PANCREATIC LIPASE TEST |
| 01.05 13:33 | dpa-AFX: IDEXX Laboratories Q1 24 Earnings Conference Call At 8:30 AM ET |
| 01.05 13:12 | dpa-AFX: ROUNDUP: IDEXX Laboratories Q1 Profit Up, Beats Estimates; Trims Annual Outlook |
| 01.05 12:40 | dpa-AFX: IDEXX Laboratories Inc Announces Advance In Q1 Bottom Line, Beats estimates |
| 01.05 12:39 | dpa-AFX: *IDEXX LABS NOW EXPECTS FY24 REVENUE OF $3.895 BLN - $3.965 BLN, EPS OF $10.82 - $11.20 |
| 01.05 12:37 | dpa-AFX: *IDEXX LABS Q1 GROSS PROFIT $593.07 MLN VS. $542.97 MLN LAST YEAR |
| 01.05 12:37 | dpa-AFX: *IDEXX LABS Q1 REVENUE $964.10 MLN VS. $900.19 MLN LAST YEAR |
| 01.05 12:36 | dpa-AFX: *IDEXX LABS Q1 OPERATING INCOME $298.96 MLN VS. $280.40 MLN LAST YEAR |
| 01.05 12:35 | dpa-AFX: *IDEXX LABS Q1 NET INCOME $235.58 MLN VS. $214.05 MLN LAST YEAR |
| 01.05 12:35 | dpa-AFX: *IDEXX LABS Q1 COMPARABLE EPS $2.71 VS. $2.49 LAST YEAR |
| 01.05 12:35 | dpa-AFX: *IDEXX LABS Q1 EPS $2.81 VS. $2.55 LAST YEAR |
|
|
